An analysis of the tasimelteon's phase III study is as troubling as the first.
These stocks look poised to break out and trade higher from current levels.
Why is Vanda spending a huge amount of money in cash bonuses to a consultant working to get its sleep disorder drug approved?
The most recent short interest data has been released by the NASDAQ for the 07/15/2013 settlement date, which shows a 1,018,126 share increase in total short interest for Vanda Pharmaceuticals Inc , to 3,547,106, an increase of 40.26% since 06/28/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
These stocks look ready to break out and trade higher from current levels.
The Law Offices of Todd M. Garber announces that it is investigating potential claims against Vanda Pharmaceuticals, Inc.
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor, LLP announce that a federal class action...
Clovis Oncology and Stemline Therapeutics were among the best-performing biotech stocks in the June quarter.
Shareholder law firm Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Vanda Pharmaceuticals, Inc.
Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
Levi & Korsinsky is investigating potential claims on behalf of purchasers of Vanda Pharmaceuticals, Inc.
The law firm of Wohl & Fruchter LLP announces that it is investigating possible violations of federal securities laws by officers and directors of Vanda Pharmaceuticals, Inc.
Stock futures are wavering Wednesday as investors eagerly await the conclusion of the two-day Federal Reserve meeting.
FDA approval of tasimelteon is unlikely because Vanda changed the study design and mis-enrolled patients.
The market could take off on a bullish surprise, but binary events are always tough to trade.
Investors eyeing a purchase of Vanda Pharmaceuticals Inc shares, but cautious about paying the going market price of $9.27/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $7 strike, which has a bid at the time of this writing of 80 cents.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Vanda Pharmaceuticals (Nasdaq:VNDA) has been downgraded by TheStreet Ratings from from a hold to sell.
Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.
These stocks look poised to break out and trade significantly higher from current levels.
Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.
Vanda Pharmaceuticals (Nasdaq:VNDA) has been upgraded by TheStreet Ratings from a sell to hold.
Vanda's schizophrenia drug closes 2010 with just $31 million in sales, far below expectations.
Clinical Data's new antidepressant is approved but bulls want the company to be sold for an even higher premium while bears say any deal is unlikely.
These five-star stocks trade at huge discounts to fair value and could soar in 2011.
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
